Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] CLL is engaged in manufacturing pharma products on contract/loan license basis. It posted growth in its top and bottom lines for the reported periods. Boosted profits from FY24 onwards raise eyebrows and concern over its sustainability as it is operating in a highly competitive and fragmented segment. Based on its recent financial data, the issue appears fully priced. Small equity base post-IPO indicates longer gestation for migration. Only well-informed/cash surplus investors may park moderate funds for medium term. Read detail review...
Curis Lifesciences Ltd. peer comparison with similar listed entities. (As on March 31, 2025)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Curis Lifesciences Limited | 10.29 | 10.29 | 27.34 | 37.62 | Restated | ||
| Sotac Pharmaceuticals Limited | 4.32 | 4.32 | 47.99 | 18.30 | 9.00 | 2.72 | |
| Lincoln Pharmaceuticals Limited | 41.11 | 41.11 | 335.34 | 12.21 | 12.27 | 1.58 |
Notes:
Curis Lifesciences IPO Reviews, analysis and views by popular members. Read Curis Lifesciences Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Post Recommendation Manage Recommendations
Note:
Useful Articles
RHP